Abstract
The newer, potent bisphosphanates have demonstrated the most significant and consistent reduction in the risk of multiple fractures across trials. The results of large, long-term trials examining the anti-fracture efficacy of hormone replacement therapy are awaited. Based on the evidence to date the bisphosphonates are the treatments of choice for postmenopausal osteoporotic women with fracture, with HRT being the preferred treatment for early postmenopausal women with osteoporosis.
| Original language | English |
|---|---|
| Number of pages | 1 |
| Journal | Medicine Today |
| Volume | 2 |
| Issue number | 7 |
| Publication status | Published - 24 Jul 2001 |
| Externally published | Yes |